SCYNEXIS Inc SCYX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SCYX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $1.55
- Day Range
- $1.48–1.59
- 52-Week Range
- $1.35–3.87
- Bid/Ask
- $1.46 / $1.56
- Market Cap
- $56.63 Mil
- Volume/Avg
- 5 / 204,985
Key Statistics
- Price/Earnings (Normalized)
- 1.15
- Price/Sales
- 0.54
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 29
- Website
- https://www.scynexis.com
Comparables
Valuation
|
Metric
|
SCYX
|
HLVX
|
INVA
|
|---|---|---|---|
Price/Earnings (Normalized) | 1.15 | — | 9.23 |
Price/Book Value | 0.80 | 2.26 | 1.42 |
Price/Sales | 0.54 | — | 4.24 |
Price/Cash Flow | 0.83 | — | 7.94 |
Price/Earnings
SCYX
HLVX
INVA
Financial Strength
|
Metric
|
SCYX
|
HLVX
|
INVA
|
|---|---|---|---|
Quick Ratio | 5.90 | 10.37 | 7.28 |
Current Ratio | 6.26 | 10.62 | 9.03 |
Interest Coverage | 21.20 | −54.72 | 10.31 |
Quick Ratio
SCYX
HLVX
INVA
Profitability
|
Metric
|
SCYX
|
HLVX
|
INVA
|
|---|---|---|---|
Return on Assets (Normalized) | 74.63% | −34.03% | 14.79% |
Return on Equity (Normalized) | 190.31% | −42.52% | 29.29% |
Return on Invested Capital (Normalized) | 116.71% | −38.62% | 16.71% |
Return on Assets
SCYX
HLVX
INVA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Gfszwzds | Lwwykp | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Nkjbyvbqc | Lzry | $68.9 Bil | |
HLN
| Haleon PLC ADR | Qwfjnjyq | Ylqv | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Zywbhgdn | Mlnjf | $14.7 Bil | |
VTRS
| Viatris Inc | Wmkycpxv | Shdj | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Fhxdkzxw | Kdbmz | $11.9 Bil | |
CTLT
| Catalent Inc | Qjrdmhs | Nrklcl | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Ykmgrnxf | Flh | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Lckrtdjq | Fvvgz | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Vrrwjsdr | Zlcvkm | $3.5 Bil |